Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-29
2011-03-29
Chu, Yong (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S456000, C548S143000, C549S399000
Reexamination Certificate
active
07915298
ABSTRACT:
This invention provides novel salt and crystalline forms thereof of (−)4-(4-fluorophenyl)-7-[({5-[1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl}amino)-methyl]-2H-chromen-2-one. The compounds are 5-LO inhibitors and are useful for treatment of conditions such as asthma, allergic rhinitis, COPD, and atherosclerosis.
REFERENCES:
patent: 5424320 (1995-06-01), Fortin et al.
patent: 7553973 (2009-06-01), Blouin et al.
patent: 2009/0030048 (2009-01-01), Blouin et al.
patent: 2009/0227638 (2009-09-01), Blouin et al.
patent: WO2004/108720 (2004-12-01), None
patent: WO2006/099735 (2006-09-01), None
patent: WO 2006099736 (2006-09-01), None
patent: WO2007/038865 (2007-04-01), None
Gosselin Francis
Vydra Vicky
Camara Valerie J.
Chu Yong
Merck Sharp & Dohme Corp.
Yang Mollie M.
LandOfFree
Compounds and methods for leukotriene biosynthesis inhibition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for leukotriene biosynthesis inhibition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for leukotriene biosynthesis inhibition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2671098